atrial

Pradaxa® vs Warfarin

By: Kevin Lin, PharmD Candidate c/o 2015 -- The FDA recently completed an observational cohort study that compared Pradaxa® (dabigatran)…

12 years ago

The Surgeon General’s 2014 Report on Smoking

By: Ada Seldin, Staff Editor - Since the first release of the Surgeon General’s Report on smoking 50 years ago,…

12 years ago

Comparison of the New Oral Antithrombotics and Warfarin

By Omar Khalid Pharm.D. Candidate c/o 2014 - The outpour of a multitude of new oral anticoagulants in recent years…

13 years ago

Two New Agents for the Treatment of Obesity

By: Nathan Trustman, PharmD Candidate c/o 2013, AMSCOP at LIU - Obesity is defined as having a body mass index…

13 years ago

FDA Approves Apixaban For Nonvalvular Atrial Fibrillation

By: Alexandra Alleva, PharmD candidate c/o 2013 - As of December 28th, Bristol-Myers Squibb and Pfizer's brand name oral anticoagulant,…

13 years ago

Antiplatelet Use Following Acute Coronary Syndromes

By: Addolorata Ciccone, Co-Copy Editor - Acute Coronary Syndromes Acute coronary syndrome (ACS) is a myocardial ischemia caused by obstruction…

14 years ago

Role of Calcium Channel Blockers and Beta Blockers in CHF

By: Lunbao Huang Pharm D. Candidate c/o 2013 - The seventh report of the Joint National Committee on high blood…

14 years ago

New Oral Direct Thrombin Inhibitors and Factor Xa Anticoagulants

By: Neal Shah - Anticlotting agents are staples in the prevention and treatment of thrombotic disorders, such as deep vein…

14 years ago

Clevidipine in the Management of Hypertensive Emergency

By: Neal Shah - Defined by the Joint National Committee, hypertension (HTN) is a systolic blood pressure (SBP) greater than…

14 years ago